The introduction is also posted on Spotify as a podcast by “Gerry at The Health Equation”

You can search Spotify for “Gerry at The Health Equation”

Or use the link below

https://podcasters.spotify.com/pod/show/gerrygaj

Below is the specific link

Gerry Gajadharsingh writes:

“One of the most persistent failures in modern healthcare is not the absence of treatment, but the failure of timely recognition. Liver disease illustrates this problem with particular clarity. Despite being largely preventable, it continues to rise quietly, often undetected until the point at which intervention becomes limited and outcomes are poor. A striking proportion of patients admitted with advanced liver disease have never previously received a diagnosis, and mortality in the weeks following admission remains unacceptably high. This is not due to a lack of contact with healthcare services, but to a fundamental mismatch between how liver disease develops and how we currently attempt to identify it.

Liver disease is typically silent in its early and mid-stages. Ongoing injury can progress for years with few, if any, clinical signs, and conventional liver function tests frequently fail to reflect this reality. Normal transaminases are often taken as reassurance, yet they correlate poorly with fibrosis or disease trajectory. Conversely, abnormal results may prompt concern without reliably indicating severity. In effect, we are often reassured when we should be vigilant, and alarmed when the signal is nonspecific. By the time cirrhosis becomes clinically apparent, the opportunity for meaningful reversal has largely passed.

This makes the launch of the largest liver study in NHS history both timely and significant. The DIALS trial represents a strategic shift away from late-stage rescue toward earlier, community-based identification of risk. Its emphasis on non-invasive testing acknowledges an important biological truth: liver disease exists along a continuum, not as a binary state, and by the time it declares itself biochemically, the underlying pathology is often well established.

From a functional clinical perspective, the strength of this approach lies in the combination of testing modalities rather than any single measure. The FIB-4 score functions primarily as a risk stratification tool, integrating age, platelet count, and liver enzymes to infer chronicity and systemic burden rather than current hepatic performance. ELF testing moves closer to the biology of disease progression, reflecting active fibrogenesis and extracellular matrix turnover—processes driven by inflammation, oxidative stress, and metabolic dysfunction rather than acute hepatocyte injury. FibroScan adds a structural dimension, capturing the cumulative mechanical consequences of fibrosis, inflammation, and congestion, independent of ALT levels. Together, these tools begin to reveal what routine blood tests often miss: the gradual, silent remodelling of liver tissue over time.

When viewed through a metabolic lens, the implications extend far beyond hepatology. The liver sits at the centre of metabolic regulation, and insulin resistance is one of the most powerful drivers of progressive liver disease. Metabolic-associated fatty liver disease is frequently the hepatic expression of a broader systemic imbalance—characterised by chronic hyperinsulinaemia, disrupted lipid handling, low-grade inflammation, poor sleep, sedentary behaviour, and persistent sympathetic activation. Alcohol, while still relevant, is often a co-factor rather than the primary cause.

Crucially, many individuals with significant metabolic liver stress never demonstrate markedly abnormal liver enzymes. Women, older adults, and those with longstanding insulin resistance are particularly likely to be overlooked. Years of lifestyle-driven strain can accumulate silently, with fibrosis advancing long before standard investigations raise concern. Yet the liver retains a remarkable capacity for regeneration. When upstream drivers are identified and addressed early—metabolic, inflammatory, behavioural, or hormonal—function often improves substantially, even in the presence of established fibrosis.

The real promise of this study, therefore, is not simply improved diagnostics, but a reframing of liver disease itself. Early identification creates a window for intervention at a stage where reversal is still possible, morbidity can be reduced, and long-term outcomes meaningfully altered. If this approach becomes embedded into routine care pathways, it has the potential to shift liver disease from a late-stage crisis to an early, preventable manifestation of systemic metabolic dysfunction—one that we can no longer afford to keep missing.”

Clinical Disclaimer

This article is intended for educational and informational purposes only. It does not constitute medical advice and should not replace individual consultation with a qualified healthcare professional.

 

Largest NHS Liver Study Targets Early Disease Detection

Medscape

Dr Sheena Meredith

The largest liver study in the history of the NHS has launched this week, aiming to detect liver disease at an early stage so treatment can begin before it progresses to cirrhosis.

Around 70% of patients admitted to hospital with late-stage liver disease were previously undiagnosed, and about a quarter die within 2 months.

According to the British Liver Trust, more than 11,000 deaths a year in the UK are attributable to liver disease. Death rates have quadrupled over the past 50 years, despite around 90% of cases being potentially preventable.

Liver disease costs the NHS an estimated £4.9 billion a year.

Liver disease is often asymptomatic. Ongoing damage can cause few obvious signs until end-stage disease has developed, when opportunities to intervene are limited.

However, the liver has a strong capacity for regeneration. If the underlying cause is removed, liver function will often improve significantly, even if fibrotic scar tissue does not fully resolve.

Early Detection Could Reduce Mortality

Liver function blood tests are commonly used to determine which patients should be referred to secondary care. However, results can be normal in the early stages of liver damage, while abnormal readings do not necessarily correlate with disease severity.

The DIALS (DIAgnosis of Liver diseaSe in primary care) trial has received £3.45 million from the National Institute for Health and Care Research to assess whether early detection and intervention can reduce hospital admissions, morbidity, and mortality.

Around 42,000 people across the UK who are considered by their GPs to be at higher risk due to obesity, type 2 diabetes or excessive alcohol intake will be offered screening for early signs of liver disease.

The trial will assess a combination of three non-invasive liver tests to identify the most efficient approach to early diagnosis:

  • Fibrosis-4 (FIB-4):a scoring system based on age, platelet count, and liver enzymes alanine transaminase (ALT) and aspartate transferase levels, used to estimate the degree of fibrosis.
  • Enhanced Liver Fibrosis (ELF):a blood test measuring levels of hyaluronic acid, procollagen 3, amino terminal peptide, and matrix metalloproteinase 1 to provide a more detailed evaluation of the degree of fibrosis.
  • FibroScan, also called transient elastography: an ultrasound technique that measures the elasticity of liver tissue to evaluate fibrosis and steatosis.

Scans will be performed irrespective of participants’ ALT levels. Patients will be referred for specialist assessment if they test positive on any of the three measures or have an indeterminate FIB-4 result.

Post hoc analysis will examine the performance of combinations — FIB-4 plus ELF, FIB-4 plus FibroScan, and ELF plus FibroScan — compared with all three tests used together. The findings are intended to inform future testing pathways for at risk patients.

Potentially Ground-Breaking Study

Emmanouil Tsochatzis, MD, PhD, co-principal investigator and professor of hepatology at University College London, and a consultant hepatologist at the Royal Free Hospital, said the study could be transformative.

“Diagnosing preventable liver disease earlier would have a profound effect in healthcare, the NHS, and society by reducing hospitalisations and costs, reducing the number of people who die at working age and improving productivity,” he said.

Tsochatzis added that early diagnosis aligns with the NHS long-term plan to shift care from hospitals to the community, and with NHS England priorities to reduce cancer risk.

“So, our aim is for this [screening] to become national policy,” he said.

The trial will run until June 2030.